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Prorenin-Induced Myocyte Proliferation
No Role for Intracellular Angiotensin II
Jasper J. Saris, Mark M.E.D. van den Eijnden, Jos M.J. Lamers, Pramod R. Saxena,
Maarten A.D.H. Schalekamp, A.H. Jan Danser
Abstract—Cardiomyocytes bind, internalize, and activate prorenin, the inactive precursor of renin, via a mannose
6-phosphate receptor (M6PR)–dependent mechanism. M6PRs couple directly to G-proteins. To investigate whether
prorenin binding to cardiomyocytes elicits a response, and if so, whether this response depends on angiotensin (Ang)
II, we incubated neonatal rat cardiomyocytes with 2 nmol/L prorenin and/or 150 nmol/L angiotensinogen, with or
without 10 mmol/L M6P, 1 mol/L eprosartan, or 1 mol/L PD123319 to block M6P and AT1 and AT2 receptors,
respectively. Protein and DNA synthesis were studied by quantifying [3H]-leucine and [3H]-thymidine incorporation. For
comparison, studies with 100 nmol/L Ang II were also performed. Neither prorenin alone, nor angiotensinogen alone,
affected protein or DNA synthesis. Prorenin plus angiotensinogen increased [3H]-leucine incorporation (215%,
meanSEM, P0.01), [3H]-thymidine incorporation (296%, P0.01), and total cellular protein (143%,
P0.01), whereas Ang II increased DNA synthesis only (347%, P0.01). Eprosartan, but not PD123319 or M6P,
blocked the effects of prorenin plus angiotensinogen as well as the effects of Ang II. Medium Ang II levels during
prorenin and angiotensinogen incubation were 1 nmol/L. In conclusion, prorenin binding to M6PRs on cardiomyo-
cytes per se does not result in enhanced protein or DNA synthesis. However, through Ang II generation, prorenin is
capable of inducing myocyte hypertrophy and proliferation. Because this generation occurs independently of M6PRs,
it most likely depends on the catalytic activity of intact prorenin in the medium (because of temporal prosegment
unfolding) rather than its intracellular activation. Taken together, our results do not support the concept of Ang II
generation in cardiomyocytes following intracellular prorenin activation. (Hypertension. 2002;39[part 2]:573-577.)
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Cardiac angiotensin synthesis depends on renin of renalorigin, both under normal and pathological condi-
tions.1–4 Circulating kidney-derived renin diffuses into the
cardiac interstitial space,5,6 and/or may bind to renin recep-
tors.7–9 In addition, the heart may sequester prorenin, the
precursor of renin, from the circulation. Prorenin could
contribute to angiotensin generation at cardiac tissue sites,
either because of its inherent catalytic activity, which is the
consequence of temporal prosegment unfolding,10,11 or fol-
lowing its local conversion to renin. In support of this
concept, we have recently demonstrated that cardiac myo-
cytes and fibroblasts are capable of binding and internalizing
recombinant human renin and prorenin via mannose
6-phosphate/insulin-like growth factor II (M6P/IGFII) recep-
tors, and that prorenin following its internalization is rapidly
activated to renin by proteolytic cleavage of the
prosegment.12,13
Recombinant as well as native human renin and prorenin
contain the M6P signal that is required to bind to M6P/IGFII
receptors.14–16 These receptors also contain binding domains
for IGFII and retinoic acid,17,18 and binding of the latter
agonists to M6P/IGFII receptors results in second messenger
activation and growth inhibition, respectively.19,20 Moreover,
proliferin, which, similar to (pro)renin, binds to M6P/IGFII
receptors via its M6P group,21 has been reported to induce
endothelial cell chemotaxis via these receptors in a G-protein-
and mitogen-activated protein kinase-dependent manner.22 In
this respect, it is of interest to note that renin binding to
mesangial cells resulted in enhanced 3H-thymidine incorpo-
ration and plasminogen-activator inhibitor-1 (PAI-1) release,
without intermediate angiotensin generation.9
M6P/IGFII receptor-mediated accumulation of renin and
activated prorenin in cardiac cells may result in intracellular
angiotensin generation, and such intracellular angiotensin
synthesis could underlie the stretch-mediated release of an-
giotensin II (Ang II) that has been demonstrated in myo-
cytes.23,24 However, to allow intracellular Ang II synthesis,
the intracellular presence of angiotensinogen and ACE is also
required, and in previous studies we were unable to detect
angiotensinogen synthesis by cardiomyocytes.25
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In the present study, we set out to investigate whether
prorenin binding, internalization, and activation by neonatal
rat cardiomyocytes results in a cellular response, either
directly (without intermediate Ang II generation), via binding
to M6P/IGFII receptors, or indirectly, via the generation of
Ang II and subsequent AT receptor activation. We measured
protein and DNA synthesis following incubation of cells with
recombinant human prorenin with or without angiotensino-
gen. Experiments were repeated in the presence of M6P,
eprosartan, and PD123319, to antagonize M6P/IGFII -, AT1 -,
and AT2 receptors, respectively. For comparison, we also
studied the effect of Ang II in the presence and absence of
these antagonists. Finally, we investigated Ang I and II
generation during incubation of myocytes with prorenin and
angiotensinogen, taking into consideration that prorenin itself
displays catalytic activity (ie, without prosegment cleavage).
Methods
Cell Culture
All experiments were performed according to the regulations of the
Animal Care Committee of the Erasmus University Medical Center
Rotterdam, in accordance with the “Guiding Principles” of the
American Physiological Society.
Primary cultures of neonatal Wistar rat (Harlan) cardiomyocytes
were prepared as previously described.12,13 Cells were seeded in
noncoated 24-well plates (Corning Costar), giving a confluent
monolayer of spontaneously beating myocytes at 1.5105 cells/cm2
after a 24-hour incubation in 1.5 mL medium (consisting of DMEM
and Medium 199 [4:1], supplemented with 5% fetal calf serum [Life
Technologies], 5% horse serum [Sigma], 100 U/mL penicillin, and
100 mg/mL streptomycin [Roche]). Thereafter, cells were incubated
for 48 hours in medium supplemented with 5% horse serum and for
24 hours in serum-free medium. Before the start of each experiment,
cells were rinsed 3 times with 1 mL warm (37°C) phosphate-
buffered saline. Next, myocytes were incubated for 24 hours at 37°C
with 250 L serum-free medium, supplemented with 1% bovine
serum albumin (BSA), and containing 100 U/L (2 nmol/L)
recombinant human prorenin (a kind gift of Dr S. Mathews,
Hoffmann-LaRoche, Basel, Switzerland) and/or 150 nmol/L human
angiotensinogen (Sigma) in the presence or absence of 10 mmol/L
M6P, 1 mol/L eprosartan, or 1 mol/L PD123319. For comparison,
experiments with 100 nmol/L Ang II (Bachem) were also performed.
Cells incubated without prorenin, angiotensinogen, or Ang II served
as control.
Protein and DNA Synthesis
Protein and DNA synthesis rates were determined in triplicate by
quantifying [3H]-leucine and [3H]-thymidine incorporation during
the last 6 hours of the above 24-hour incubation period in the
presence of Ang II or prorenin and/or angiotensinogen.26 Total
cellular protein and DNA were quantified after solubilization as
described previously using BSA and salmon sperm as standard,
respectively.26
Angiotensin Generation
To measure angiotensin generation, myocytes were cultured in
6-well plates, and incubated at 37°C for 4 hours with 1 mL medium
containing 10 or 100 U/L recombinant human prorenin and/or 150
nmol/L angiotensinogen. Cells incubated without prorenin or angio-
tensinogen served as control. After 1 hour and 4 hours of incubation,
75 L medium was rapidly mixed with 6 L inhibitor solution27 and
frozen at 70°C. Cells were collected after 4 hours (when the
cellular levels of activated prorenin are maximal12,13) as described
before.27 Ang I and Ang II levels in medium were measured by
radioimmunoassay (detection limit 40 and 20 fmol/mL, respective-
ly).25,27 Ang I and II levels in cell homogenates were measured by
radioimmunoassay after SepPak extraction and reversed-phase high-
performance liquid chromatography separation (detection limit 0.4
and 0.2 fmol/106 cells).25,27 For comparison, cellular angiotensin
levels following a 4-hour incubation with 100 nmol/L Ang II were
also measured.
Statistical Analysis
Data are expressed as meanSEM. Statistical analysis was by
ANOVA, followed by post-hoc evaluation according to Dunnett
where appropriate. Statistical significance was accepted at P0.05.
Results
Protein and DNA Synthesis
The total cellular protein and DNA contents of myocytes,
following a 24-hour incubation with vehicle, were 14714 and
8.31.0 g/well (n15–16), respectively. Incorporation of
3H-leucine and 3H-thymidine during the last 6 hours of the
24-hour incubation period amounted to 279013707 and
574036262 dpm/well (n16), respectively. None of the re-
ceptor blockers affected protein or DNA content or incorpora-
tion of 3H-leucine and 3H-thymidine (n8 for each blocker, data
not shown). Prorenin alone and angiotensinogen alone were
without effect (Figure 1). Prorenin (2 nmol/L) combined with
angiotensinogen increased total cellular protein (P0.01), 3H-
leucine incorporation (P0.01), and 3H-thymidine incorporation
(P0.01), whereas Ang II increased the latter (P0.01) only.
The effects of prorenin combined with angiotensinogen were not
observed at a prorenin concentration of 0.2 nmol/L (n10, data
not shown). All effects of prorenin combined with angioten-
sinogen as well as the effect of Ang II on 3H-thymidine
incorporation were blocked by eprosartan but not PD123319 or
M6P (Figures 2 and 3). PD123319 tended to enhance the effects
of Ang II on total cellular protein, but the difference was not
significant (Figure 3).
Angiotensin Generation
Ang I and Ang II were undetectable in medium or cells under
control conditions and following incubations with either
prorenin alone or angiotensinogen alone. At 1 hour after the
addition of 2 nmol/L prorenin combined with 150 nmol/L
Figure 1. Effect of 2 nmol/L prorenin, 150 nmol/L angiotensino-
gen, 2 nmol/L prorenin plus 150 nmol/L angiotensinogen, and
100 nmol/L angiotensin (Ang) II on total cellular protein content,
total cellular DNA content, [3H]-leucine incorporation, and
[3H]-thymidine incorporation in cardiomyocytes. Data are
expressed as percentage change from control (meanSEM of
8–16 experiments). PR indicates prorenin; Aog, angiotensino-
gen. *P0.01 versus control.
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angiotensinogen to the cells, Ang I and Ang II levels in the
medium were 4278207 and 37223 pmol/L (n3), and
after 4 hours these levels amounted to 4704462 and
795102 pmol/L. When using 0.2 nmol/L prorenin in com-
bination with 150 nmol/L angiotensinogen, the Ang I and
Ang II levels in the medium were 656161 and 8514
pmol/L after 1 hour (n3), and 87643 and 12918 pmol/L
after 4 hours. Cellular Ang I levels measured after 4 hours of
incubation with prorenin and angiotensinogen or 100 nmol/L
Ang II were below the detection limit (n3 for each
condition). Cellular Ang II levels were also undetectable
following a 4-hour incubation with 0.2 nmol/L prorenin
combined with 150 nmol/L angiotensinogen. However, at a
10-fold higher prorenin concentration, as well as following a
4-hour incubation with 100 nmol/L Ang II, cellular Ang II
levels amounted to 1.30.5 and 1.90.3 fmol/106 cells,
respectively (n3 for each condition). These levels represent
0.5% of the levels in the medium.
Discussion
Prorenin binding to M6P/IGFII receptors located on the cell
surface of neonatal rat cardiomyocytes does not result in
enhanced protein or DNA synthesis. Enhanced protein and
DNA synthesis were observed however when exposing the
cells to prorenin combined with angiotensinogen, suggesting
that these effects depend on angiotensin generation. Because
prorenin binding to M6P/IGFII receptors is followed by
internalization and rapid intracellular activation to renin,
without subsequent release of renin to the medium,12,13 we
reasoned that intracellular angiotensin synthesis might under-
lie these findings. Such intracellular angiotensin generation
will not occur in the absence of prorenin, because neonatal rat
cardiomyocytes do not synthesize renin in detectable
amounts.25 However, the addition of 10 mmol/L M6P to the
medium, which fully blocks prorenin internalization and
activation,12,13 did not block the prorenin plus angioten-
sinogen-induced effects on DNA and protein synthesis. Re-
markably, blockade was observed with the AT1 receptor
antagonist eprosartan, while the AT2 receptor antagonist
PD123319, like M6P, was without effect. In view of the
virtual lack of internalization of receptor antagonists,28 the
most likely explanation for these findings is that the inherent
catalytic activity of prorenin, caused by temporal unfolding of
the prosegment, results in extracellular Ang II generation and
subsequent AT1 receptor stimulation. In support of this
concept, Ang I and Ang II could be detected in nanomolar
concentrations in the medium during incubation of the cells
with 2 nmol/L prorenin and 150 nmol/L angiotensinogen.
The lack of effect of prorenin binding per se was unex-
pected, because several groups have reported that binding of
M6P-containing glycoproteins to M6P/IGFII receptors results
in a cellular response in a G-protein-dependent manner, eg,
chemotaxis or increased c-fos expression.19,22 Moreover,
binding of renin to human mesangial cells was found to
enhance 3H-thymidine incorporation and PAI-1 release, inde-
pendent of angiotensin generation.9 The receptor mediating
the latter effect has not yet been identified and is not
necessarily the M6P/IGFII receptor.9 Furthermore, the IGFII
analog [Leu27]IGFII, which binds to the M6P/IGFII receptor
with equal affinity as IGFII, induced chemotaxis but not
DNA synthesis.29,30 Therefore, taken together, it is still very
well possible that prorenin binding to M6P/IGFII receptors
elicits other cellular responses than protein and DNA
synthesis.
The addition of human angiotensinogen to the medium did
not result in protein or DNA synthesis. This suggests that
neonatal rat cardiomyocytes, like mouse cardiomyocytes,31
do not posses enzymes (eg, cathepsins) capable of cleaving
human angiotensinogen into Ang I and des-angiotensinogen.
Ang I generation only occurred when combining human
prorenin with human angiotensinogen, and this generation
was limited to the extracellular compartment. The absence of
intracellular Ang I, despite the proteolytic cleavage of prore-
nin to renin in myocytes, is in agreement with previous
studies showing neither binding of angiotensinogen to cardiac
Figure 2. Effect of 2 nmol/L prorenin plus 150 nmol/L angioten-
sinogen on total cellular protein content, total cellular DNA con-
tent, [3H]-leucine incorporation, and [3H]-thymidine incorporation
in cardiomyocytes in the presence of vehicle (none), the AT1
receptor antagonist eprosartan (Epro; 1 mol/L), the AT2 recep-
tor antagonist PD123319 (1 mol/L), or the M6P/IGFII receptor
antagonist M6P (10 mmol/L). Data are expressed as percentage
change from control (meanSEM of 8 experiments). #P0.05
versus none.
Figure 3. Effect of 100 nmol/L Ang II on total cellular protein
content, total cellular DNA content, [3H]-leucine incorporation,
and [3H]-thymidine incorporation in cardiomyocytes in the pres-
ence of vehicle (none), the AT1 receptor antagonist eprosartan
(Epro; 1 mol/L), the AT2 receptor antagonist PD123319 (1
mol/L), or the M6P/IGFII receptor antagonist M6P (10 mmol/L).
Data are expressed as percentage change from control
(meanSEM of 8 experiments). #P0.05, *P0.01 versus none.
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and vascular membrane fractions,1,8 nor angiotensinogen
internalization.27 Apparently, the intracellular presence of
Ang II in myocytes must be explained on the basis of AT1
receptor-mediated endocytosis,32–34 rather than intracellular
Ang II generation. In support of this contention, Ang II was
also detected in cell lysates following a 4-hour incubation
with 100 nmol/L Ang II. Furthermore, the low cellular Ang II
levels during incubation with prorenin plus angiotensinogen
(0.5% of the levels in the medium) also argue against
synthesis and/or storage of Ang II in myocytes.23
In the present study, extracellular Ang I generation oc-
curred in a prorenin concentration-dependent manner. At the
highest prorenin concentration tested (2 nmol/L), the Ang I
levels in the medium reached a steady state within 4 hours.
The levels were in the order of 5 nmol/L, which is within the
range expected based on the concept that 2% of prorenin is
catalytically active.27 We previously reported that, in the
absence of serum, Ang I–II conversion by ACE on myocytes
is responsible for approximately 50% of Ang I metabolism by
neonatal rat cardiomyocytes, and that the Ang I half life under
these conditions is 1 hour.25 The Ang II half life is much
longer,26 and this may explain why the medium Ang II levels
in the present study continued to rise between 1 and 4 hours.
Importantly however, the Ang II levels in the medium after 4
hours of prorenin plus angiotensinogen incubation were less
than 1 nmol/L, and it is unlikely, in view of the steady-state
Ang I levels, that these levels would have become much
higher on longer incubation. Yet, despite these relatively low
Ang II levels, the effects of prorenin combined with angio-
tensinogen on protein and DNA synthesis were equal to or
stronger than those of 100 nmol/L Ang II. There are several
explanations for this apparent discrepancy. First, Ang I–II
conversion by ACE may occur in close proximity of AT1
receptors and may thus result in higher Ang II levels in the
microenvironment of these receptors than in the medium.35
Second, long-term exposure to low levels of Ang II (as a
consequence of continuous Ang II generation) might be more
efficient to induce cellular responses than short-term expo-
sure to high levels of Ang II, for instance because the latter
results in rapid downregulation of AT1 receptors.36 Finally,
because neonatal rat cardiomyocytes possess both AT1 and
AT2 receptors, Ang II may also stimulate AT2 receptors, and
this could counteract the AT1 receptor-induced effects.26,37 It
is possible that ACE-dependent local Ang II generation
predominantly leads to AT1 receptor activation, because ACE
is located in close proximity of AT1 receptors,38 whereas
exogenous Ang II results in equal AT1 and AT2 receptor
activation. In agreement with this concept, as in our previous
study,26 the Ang II-mediated effect on total cellular protein
increased in the presence of PD123319 (Figure 3).
The effects of locally generated and exogenous Ang II on
protein and DNA synthesis rate were of modest proportion
and exceeded those on total cellular protein and DNA
content, suggesting that they may have been counterbalanced,
at least in part, by protein and DNA degradation.
In conclusion, the partial catalytic activity of prorenin is
responsible for the enhanced protein and DNA synthesis
observed in cardiomyocytes during their incubation with
prorenin and angiotensinogen. We found no evidence for
intracellular angiotensin generation in these cells, nor did
prorenin binding to M6P/IGFII receptors per se result in cell
proliferation.
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